Get Cash Back and $0 Commissions
+ The Power of TradeStation

Cantor Fitzgerald Initiates Coverage On Eupraxia Pharmaceuticals with Overweight Rating, Announces Price Target of $11

Benzinga Newsdesk 24-Jul-2025 7:08 AM

Cantor Fitzgerald analyst Kristen Kluska initiates coverage on Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Overweight rating and announces Price Target of $11.